Pharmacogenetics and Schizophrenia

Craddock, 2005, The genetics of schizophrenia and bipolar disorder: dissecting psychosis, J Med Genet, 42, 193, 10.1136/jmg.2005.030718 Kirov, 2005, Finding schizophrenia genes, J Clin Invest, 115, 1440, 10.1172/JCI24759 Lane, 2005, Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics, Pharmacogenomics, 6, 139, 10.1517/14622416.6.2.139 Malhotra, 2004, Pharmacogenetics of psychotropic drug response, Am J Psychiatry, 161, 780, 10.1176/appi.ajp.161.5.780 Kirchheiner, 2004, Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response, Mol Psychiatry, 9, 442, 10.1038/sj.mp.4001494 Bishop, 2004, Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response, Pharmacogenomics, 5, 463, 10.1517/14622416.5.5.463 Roses, 2004, Pharmacogenetics and drug development: the path to safer and more effective drugs, Nat Rev Genet, 5, 645, 10.1038/nrg1432 Aitchison, 2005, Psychiatry and the “new genetics”: hunting for genes for behaviour and drug response, Br J Psychiatry, 186, 91, 10.1192/bjp.186.2.91 Lopez-Garcia, 2006, Association between clozapine-induced agranulocytosis and HLA subtyping, J Clin Psychiatry, 67, 1652, 10.4088/JCP.v67n1024e Pouzet, 2002, Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia, Pharmacol Biochem Behav, 71, 635, 10.1016/S0091-3057(01)00743-2 Jablensky, 2004, Resolving schizophrenia's CATCH22, Nat Genet, 36, 674, 10.1038/ng0704-674 Meltzer, 1999, The role of serotonin in antipsychotic drug action, Neuropsychopharmacology, 21, 106, 10.1016/S0893-133X(99)00046-9 Itokawa, 1996, Sequestration of the short and long isoforms of dopamine D2 receptors expressed in Chinese hamster ovary cells, Mol Pharmacol, 49, 560 Schafer, 2001, Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene, Am J Psychiatry, 158, 802, 10.1176/appi.ajp.158.5.802 Dubertret, 2004, The 3′ region of the DRD2 gene is involved in genetic susceptibility to schizophrenia, Schizophr Res, 67, 75, 10.1016/S0920-9964(03)00220-2 Arinami, 1997, A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia, Hum Mol Genet, 6, 577, 10.1093/hmg/6.4.577 Jonsson, 1999, Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers, Mol Psychiatry, 4, 290, 10.1038/sj.mp.4000532 Wu, 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients, Neurosci Lett, 376, 1, 10.1016/j.neulet.2004.11.014 Parsons, 2004, Association of a D2 receptor gene polymorphism with schizophrenia and treatment response in the Basque and Spanish populations, Am J Med Genet [B], 130, 164 Yamanouchi, 2003, Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone, Pharmacogenomics J, 3, 356, 10.1038/sj.tpj.6500211 Kay, 1987, The Positive and Negative Syndrome Scale (PANSS) for schizophrenia, Schizophr Bull, 13, 261, 10.1093/schbul/13.2.261 Reynolds, 2005, Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response, Eur Neuropsychopharmacol, 15, 143, 10.1016/j.euroneuro.2004.07.001 Lencz, 2006, DRD2 promoter region as a predictor of sustained response to antipsychotic medication in first episode schizophrenia patients, Am J Psychiatry, 163, 529, 10.1176/appi.ajp.163.3.529 Lane, 2004, Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function, Int J Neuropsychopharmacol, 7, 461, 10.1017/S1461145704004389 Kapur, 2001, Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? A new hypothesis, Am J Psychiatry, 158, 360, 10.1176/appi.ajp.158.3.360 Arranz, 1995, Association between clozapine response and allelic variation in 5_HT2A receptor gene, Lancet, 346, 281, 10.1016/S0140-6736(95)92168-0 Lane, 2002, Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene, Am J Psychiatry, 159, 1593, 10.1176/appi.ajp.159.9.1593 Polesskaya, 2002, Differential expression of the “C” and “T” alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics, J Neurosci Res, 67, 812, 10.1002/jnr.10173 Ellingrod, 2003, 5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia, Psychopharmacol Bull, 37, 109 Ellingrod, 2002, 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia, J Clin Psychopharmacol, 22, 622, 10.1097/00004714-200212000-00014 Davies, 2006, Pharmacologic analysis of non synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotics and agonist efficacies, Pharmacogenomics J, 6, 42, 10.1038/sj.tpj.6500342 Reynolds, 2005, The role of 5HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment, Prog Neuropsychopharmacol Biol Psychiatry, 29, 1021, 10.1016/j.pnpbp.2005.03.019 Lane, 2004, Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounds, Schizophr Res, 67, 63, 10.1016/j.schres.2003.08.006 Otano, 1999, Anxiogenic-like effects and reduced stereological counting of immunolabelled 5-hydroxytryptamine6 receptors in rat nucleus accumbens by antisense oligonucleotides, Neuroscience, 92, 1001, 10.1016/S0306-4522(99)00066-4 Meneses, 2001, Effects of the 5-HT(6) receptor antagonist Ro 04-6790 on learning consolidation, Behav Brain Res, 118, 107, 10.1016/S0166-4328(00)00316-8 Malhotra, 1998, A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics, Mol Psychiatry, 3, 328, 10.1038/sj.mp.4000412 Overall, 1962, The brief psychiatric rating scale, Psychol Rep, 10, 799, 10.2466/pr0.1962.10.3.799 Fromm, 2004, Importance of P-glycoprotein at blood-tissue barriers, Trends Pharmacol Sci, 25, 423, 10.1016/j.tips.2004.06.002 Marzolini, 2004, Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance, Clin Pharmacol Ther, 75, 13, 10.1016/j.clpt.2003.09.012 Hoffmeyer, 2000, Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, Proc Natl Acad Sci U S A, 97, 3473, 10.1073/pnas.97.7.3473 Tanabe, 2001, Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene, J Pharmacol Exp Ther, 297, 1137 Woodahl, 2004, The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function, Curr Drug Metab, 5, 11, 10.2174/1389200043489108 Wang, 2004, Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals, Neuropsychopharmacology, 29, 551, 10.1038/sj.npp.1300372 Doran, 2005, The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model, Drug Metab Dispos, 33, 165, 10.1124/dmd.104.001230 Boulton, 2002, In vitro P-glycoprotein affinity for atypical and conventional antipsychotics, Life Sci, 71, 163, 10.1016/S0024-3205(02)01680-6 Lin, 2006, The relationship between P-glycoprotein (PGP) and response to olanzapine treatment in schizophrenia, Ther Drug Monit, 28, 668, 10.1097/01.ftd.0000246761.82377.a6 Blundell, 1984, Serotonin and appetite, Neuropharmacology, 23, 1537, 10.1016/0028-3908(84)90098-4 Liebowitz, 1990, Anxiety and depression: discrete diagnostic entities?, J Clin Psychopharmacol, 10, 61S, 10.1097/00004714-199006001-00012 Wurtman, 1993, Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers, Neuropsychopharmacology, 9, 201, 10.1038/npp.1993.56 Davis, 1996, Dexfenfluramine. An updated review of its therapeutic use in the management of obesity, Drugs, 52, 696, 10.2165/00003495-199652050-00007 Tecott, 1995, Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors, Nature, 374, 542, 10.1038/374542a0 Morimoto, 1999, Involvement of the histaminergic system in leptin-induced suppression of food intake, Physiol Behav, 67, 679, 10.1016/S0031-9384(99)00123-7 Baptista, 1999, Body weight gain induced by antipsychotic drugs: mechanisms and management, Acta Psychiatr Scand, 100, 3, 10.1111/j.1600-0447.1999.tb10908.x Reynolds, 2002, Association of antipsychotic induced weight gain with a 5HT2 receptor gene polymorphism, Lancet, 359, 2086, 10.1016/S0140-6736(02)08913-4 Basile, 2002, Serotonin 2C receptor gene and clozapine-induced weight gain, Lancet, 360, 1790, 10.1016/S0140-6736(02)11706-5 Tsai, 2002, 759C/T genetic variation of 5HT2c receptor and clozapine-induced weight gain, Lancet, 360, 1790, 10.1016/S0140-6736(02)11705-3 Reynolds, 2003, Clozapine-induced weight gain associated with a polymorphism of the promotor region of the 5-HT2C receptor gene, Am J Psychiatry, 160, 677, 10.1176/appi.ajp.160.4.677 Ellingrod, 2005, Weight gain associated with the -759 C/T polymorphism of the 5HT2C receptor and olanzapine, Am J Med Genet B Neuropsychiatr Genet, 134, 76, 10.1002/ajmg.b.20169 Miller, 2005, Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism, Am J Med Genet B Neuropsychiatr Genet, 133, 97, 10.1002/ajmg.b.30115 Buckland, 2005, Low gene expression conferred by association of an allele of the 5HT2c receptor gene with antipsychotic-induced weight gain, Am J Psychiatry, 162, 613, 10.1176/appi.ajp.162.3.613 Templeman, 2005, Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis, Pharmacogenet Genomics, 15, 195, 10.1097/01213011-200504000-00002 Basile, 2001, Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle, J Clin Psychiatry, 62, 45 Miller, 2005, Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial, Schizophr Res, 80, 33, 10.1016/j.schres.2005.07.034 Meshul, 1989, Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment, Brain Res, 489, 338, 10.1016/0006-8993(89)90867-6 Zai CC, Hwang RW, De Luca V, et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol; Published online. Cambridge, UK: Cambridge University Press; September 7, 2006. Guy, 1976, Abnormal involuntary movement scale, 534 Badri, 1996, Dopamine and serotonin system genes may predict clinical response to clozapine. In: Proceedings of the 46th Annual Meeting of the American Society of Human Genetics, Am J Hum Genet, 59, A247 Steen, 1997, Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients, Mol Psychiatry, 2, 139, 10.1038/sj.mp.4000249 Basile, 1999, Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia, Neuropsychopharmacology, 21, 17, 10.1016/S0893-133X(98)00114-6 Segman, 1999, Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia, Mol Psychiatry, 4, 247, 10.1038/sj.mp.4000511 Liao, 2001, Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients, Neuropsychobiology, 44, 95, 10.1159/000054924 Lovlie, 2000, Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients, Int J Neuropsychopharmacol, 3, 61, 10.1017/S1461145700001796 Woo, 2002, Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics, Psychiatry Clin Neurosci, 56, 469, 10.1046/j.1440-1819.2002.01038.x Lerer, 2002, Pharmacogenetics of tardive dyskinesia. Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism, Neuropsychopharmacology, 27, 105, 10.1016/S0893-133X(02)00293-2 de Leon, 2005, Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness, J Clin Psychopharmacol, 25, 448, 10.1097/01.jcp.0000177546.34799.af Inada, 1997, Search for a susceptibility locus to tardive dyskinesia, Hum Psychopharmacol Clin Exp, 12, 35, 10.1002/(SICI)1099-1077(199701/02)12:1<35::AID-HUP828>3.0.CO;2-# Rietschel, 2000, Dopamine D3 receptor variant and tardive dyskinesia, Eur Arch Psychiatry Clin Neurosci, 250, 31, 10.1007/PL00007536 Garcia-Barcelo, 2001, Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients, J Neural Transm, 108, 671, 10.1007/s007020170044 Potkin, 2002, Combining brain imaging and pharmacogenetics in understanding clinical response in Alzheimer's disease and schizophrenia Srivastava, 2006, Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV role of dopaminergic pathway gene polymorphisms, Pharmacogenet Genomics, 16, 111, 10.1097/01.fpc.0000184957.98150.0f Segman, 2001, Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia, Mol Psychiatry, 6, 225, 10.1038/sj.mp.4000842 Tan, 2001, Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor, Biol Psychiatry, 50, 144, 10.1016/S0006-3223(01)01076-9 Lerer, 2005, Combined analysis of 635 patients confirms an age related association of serotonin 2A receptor gene with tardive dyskinesia and specificity for non-orofacial subtype, Int J Neuropsychopharmacol, 8, 411, 10.1017/S1461145705005389 Basile, 2001, Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia, Mol Psychiatry, 6, 230, 10.1038/sj.mp.4000847 Zhang, 2002, Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia, Mol Psychiatry, 7, 670, 10.1038/sj.mp.4001052 Ingelman-Sundberg, 2004, Pharmacogenetics of cytochrome P450 and its applications to drug therapy: the past, the present and the future, Trends Pharmacol Sci, 25, 3, 10.1016/j.tips.2004.02.007 De Leon, 2006, Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19, Psychosomatics, 47, 75, 10.1176/appi.psy.47.1.75 Bradford, 2002, CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants, Pharmacogenomics, 3, 229, 10.1517/14622416.3.2.229 Kapitany, 1998, Genetic polymorphism for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia, Schizophr Res, 32, 101, 10.1016/S0920-9964(98)00038-3 Ohmori, 1998, Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics, Schizophr Res, 32, 107, 10.1016/S0920-9964(98)00018-8 Ellingrod, 2000, Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score, Psychiatr Genet, 10, 9, 10.1097/00041444-200010010-00002 Kirch, 1988, Hypothesis: a nicotine dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia, Cell Mol Neurobiol, 8, 285, 10.1007/BF00711170 Yassa, 1987, Nicotine exposure and tardive dyskinesia, Biol Psychiatry, 22, 67, 10.1016/0006-3223(87)90131-4 Miller, 1990, The influence of cigarette smoking on haloperidol pharmacokinetics, Biol Psychiatry, 28, 529, 10.1016/0006-3223(90)90488-N Ellingrod, 2002, Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6, Pharmacotherapy, 22, 1416, 10.1592/phco.22.16.1416.33700 Sachse, 1997, Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences, Am J Hum Genet, 60, 284 Basile, 2000, A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia, Mol Psychiatry, 5, 410, 10.1038/sj.mp.4000736 Schulze, 2001, Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia, Am J Med Genet, 105, 498, 10.1002/ajmg.1472 Serretti, 2005, The influence of serotonin transporter polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments, Prog Neuropsychopharmacol Biol Psychiatry, 29, 1074, 10.1016/j.pnpbp.2005.03.013 Blasi, 2006, Imaging genomics and response to treatment with antipsychotics in schizophrenia, NeuroRx, 3, 117, 10.1016/j.nurx.2005.12.001 Bertolino, 2004, Interaction of COMT Val108/158Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia, Am J Psychiatry, 10, 1798, 10.1176/appi.ajp.161.10.1798 Chou, 2000, Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness, J Clin Psychopharmacol, 20, 246, 10.1097/00004714-200004000-00019 Perlis, 2005, Pharmacogenetic testing in the clinical management of schizophrenia, a decision analytic model, J Clin Psychopharmacol, 25, 427, 10.1097/01.jcp.0000177553.59455.24